BAYER EXPECTS UPLIFT IN PHARMACEUTICALS BUSINESS

Bayer said it had "great confidence for the future," announcing at an investor conference that its experimental cancer drug had blockbuster sales potential and progress on other treatments. The German chemicals and pharmaceuticals group doubled its sales estimates for Nexavar to more than €1bn a year as it expanded clinical tests to include lung cancer. Bayer said a Phase III clinical trial for lung cancer would begin in the first half of next year, while the drug, under review by regulators, was expected to launch next year to treat kidney cancer.

MSNBC (http://msnbc.msn.com/id/10377950/)